Rosen Law Firm notifies PROCEPT BioRobotics investors of Sept. 22 deadline

Rosen Law Firm says investors who bought PROCEPT BioRobotics common stock during a stated class period may seek lead-plaintiff status in a pending securities case.

Rosen Law Firm said in a notice dated Aug. 26, 2026, and published Aug. 27 UTC that it is notifying purchasers of PROCEPT BioRobotics Corp. common stock, ticker PRCT, about a pending securities class action. The notice says investors who bought shares from Feb. 28, 2024, through Feb. 25, 2026, inclusive, may be eligible to participate and that the deadline to ask the court to serve as lead plaintiff is Sept. 22, 2026.

Rosen said eligible investors may be able to pursue compensation on a contingency-fee basis, meaning fees and costs would come from any recovery rather than upfront payments, according to the notice.

The filing says a class action has already been filed. It also says investors who want to serve as lead plaintiff must move the court by the Sept. 22 deadline. The notice describes a lead plaintiff as a representative party acting on behalf of other class members in directing the case.

Rosen’s notice summarizes allegations made in the lawsuit. It says the defendants allegedly failed to disclose that PROCEPT used an extensive discount program to encourage bulk orders above procedure demand, which the notice says artificially and unsustainably inflated reported U.S. handpiece unit sales and revenue by pulling forward sales.

The notice also says customer handpiece orders allegedly exceeded underlying procedure demand throughout the class period and that the gap grew over time. It says the resulting surplus created a glut of field inventory and customer overstocking, and that the overstocking amounted to more than 10,000 excess units by the end of the class period, according to the claims described in the notice.

Rosen’s summary further alleges that PROCEPT’s statements about handpiece unit sales and use of field systems were materially overstated. It says the company faced undisclosed operational and financial harm risks and could not achieve its stated 2025 handpiece sales and revenue guidance, which the notice says lacked a reasonably achievable factual basis. The notice says investors allegedly suffered damages when the true details entered the market.

The notice provides a case-join link at rosenlegal.com and lists contact information for Phillip Kim, Esq., including a toll-free phone number and email address, for investors seeking information. The notice did not include a company response.

What happens next is the Sept. 22 lead-plaintiff deadline stated in the notice. Investors who want to seek that role must move the court by that date, according to Rosen.

Sources

• PR Newswire press release

Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.